Evidence map›Paper›PMID 36590593›Full record

ArticleFrontiers in cellular and infection microbiology2022

African-specific polymorphisms in

Nobuko Arisue, Nirianne Marie Q Palacpac, Edward H Ntege, Adoke Yeka, Betty Balikagala, Bernard N Kanoi, Edith Christiane Bougouma, Alfred B Tiono, Issa Nebie, Amidou Diarra and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 5 countries.

Nobuko ArisueResearch Center for Infectious Disease Control, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Nirianne Marie Q PalacpacDepartment of Malaria Vaccine Development, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Edward H NtegeDepartment of Plastic and Reconstructive Surgery, University of the Ryukyus, Graduate School of Medicine and Hospital, Okinawa, Japan.
Adoke YekaMakerere University School of Public Health, Kampala, Uganda.
Betty BalikagalaDepartment of Tropical Medicine and Parasitology, School of Medicine, Juntendo University, Tokyo, Japan.
Bernard N KanoiCentre for Malaria Elimination (CME) and Centre for Research in Infectious Diseases (CRID), Directorate of Research and Innovation, Mount Kenya University, Thika, Kenya.
Edith Christiane BougoumaPublic Health Department, Institut National de Santé Publique/Centre National de Recherche et de Formation sur le Paludisme (INSP/CNRFP), Ouagadougou, Burkina Faso.
Alfred B TionoPublic Health Department, Institut National de Santé Publique/Centre National de Recherche et de Formation sur le Paludisme (INSP/CNRFP), Ouagadougou, Burkina Faso.
Issa NebiePublic Health Department, Institut National de Santé Publique/Centre National de Recherche et de Formation sur le Paludisme (INSP/CNRFP), Ouagadougou, Burkina Faso.
Amidou DiarraPublic Health Department, Institut National de Santé Publique/Centre National de Recherche et de Formation sur le Paludisme (INSP/CNRFP), Ouagadougou, Burkina Faso.
Sophie HouardEuropean Vaccine Initiative (EVI), Universitäts Klinikum Heidelberg, Heidelberg, Germany.
Flavia D'AlessioEuropean Vaccine Initiative (EVI), Universitäts Klinikum Heidelberg, Heidelberg, Germany.
Odile LeroyEuropean Vaccine Initiative (EVI), Universitäts Klinikum Heidelberg, Heidelberg, Germany.
Sodiomon B SirimaPublic Health Department, Institut National de Santé Publique/Centre National de Recherche et de Formation sur le Paludisme (INSP/CNRFP), Ouagadougou, Burkina Faso.
Thomas G EgwangMed Biotech Laboratories, Kampala, Uganda.
Toshihiro HoriiDepartment of Malaria Vaccine Development, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Groupe de Recherche et d’Action sur le Foncier · BFOsaka University · JPVienna Vaccine Safety Initiative · DECentre National de Recherche et de Formation sur le Paludisme · BFHeidelberg University · DEJuntendo University · JPMakerere University · UGMount Kenya University · KEUniversity of the Ryukyus · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BK-SE36, based on

Indexed as

Malaria, FalciparumMalaria VaccinesAntibody FormationAntigens, ProtozoanBurkina FasoClinical Trials, Phase I as TopicCross-Sectional StudiesHumansPlasmodium falciparumUgandaVaccinationAntigens, ProtozoanMalaria VaccinesBK-SE36 malaria vaccineclinical trialPlasmodium falciparumpolymorphismserine repeat antigen 5

Identifiers

PMID36590593
PMCPMC9802637
OpenAlexW4311890971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.